Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative prescription drugs used to treat a number of diseases and conditions, including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease and respiratory. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... 31, 2015 , ... Ralco is honored to announce that it is the ... be held August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience ... agriculture impacts their daily lives. This unique exhibit also features a birthing center for ...
(Date:7/30/2015)... 30, 2015   GenoSpace , a leading ... and analysis of genomic and other biomedical data, ... joined the company as Vice President of Sales ... "GenoSpace partners with its ... analyze and explore complex sets of genomic, phenotypic ...
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on ... current state of the global Propanol market with a focus on the Chinese situation. ... Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... CRY ), an implantable biological medical ... quarter financial results will be released on Thursday, April 30, ... teleconference call and live webcast at 10:00 a.m. Eastern Time ... session hosted by Steven G. Anderson, president and chief executive ...
... FACP, CPE TO JOIN NEOSTEM,S ADVISORY BOARDNEW YORK, April ... ), which is pioneering the pre-disease collection, processing and ... need, today announced that it will be moving its ... utilizing exclusively Progenitor Cell Therapy, LLC (PCT), a leading ...
... leading peer-reviewed research journal, is partnering with Applied Biosystems, a division ... Cancer Genomics to be broadcast live online at 12 noon ET ... ... 15, 2009 -- The business office of Science, the world,s leading ...
Cached Biology Technology:CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results 2NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC 2NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC 3Science Magazine to Host Webinar on Advances in Cancer Genomics 2Science Magazine to Host Webinar on Advances in Cancer Genomics 3
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... The Origin of Species 150 years ago, he deliberately avoided ... the mention of the ,Creator, in the last paragraph of ... to commit on the matter. An international team, led by ... that idea and shows that the British naturalist did explain ...
... 27, 2009 UT Southwestern Medical Center patient Michael LeBlanc, ... newest generation of a mechanical device designed to improve heart ... heart transplant. Called a left-ventricular assist device (LVAD), its ... throughout the body. For Mr. LeBlanc, it will help his ...
... City, Ireland, October 26, 2009 Results of an ... intraocular lens (IOLs) at the time of cataract surgery ... afford protection against the development and/or progression of age-related ... and vision researchers from the Macular Pigment Research Group ...
Cached Biology News:Charles Darwin really did have advanced ideas about the origin of life 2UT Southwestern patient first in North Texas to receive newest-generation heart failure device 2UT Southwestern patient first in North Texas to receive newest-generation heart failure device 3Blue light-filtering increases macular pigment, may protect against age-related vision loss 2Blue light-filtering increases macular pigment, may protect against age-related vision loss 3Blue light-filtering increases macular pigment, may protect against age-related vision loss 4
... screening and binding optimization and built on ... synthesis platform. These microarrays are available as ... Service. Probe Content Our ... 1500 known aptamer sequences. Add up to ...
... LC Sciences provides a comprehensive service ... high density peptide microarrays synthesized on ... using recombinant proteins/antibodies or serum samples. ... your sequence designs, binding assays using ...
... a comprehensive epitope analysis service utilizing ... Paraflo microfluidic chips for immunological studies, ... comprehensive service includes assistance with your ... provided by you, single or dual ...
... aptamer screening and binding optimization and built ... on-chip synthesis platform. Thousands of customer specified ... LC Sciences can provide assistance with custom ... part of our comprehensive DNA/RNA Aptamer Microarray ...
Biology Products: